Acticor Biotech Stock Quote ALACT - Stock Price, News, Charts, Message Board, Trades

Unlock more advanced trading tools

Join ADVFN today

Current Price

0.404

Bid

0.40

Ask

0.404

Volume

75,294

0.381 Day's Range 0.427

0.27 52 Week Range 6.22

Market Cap

5.276M

Previous Close

0.384

Open

0.384

Last Trade

0.404

Last Trade Time

Financial Volume

VWAP

Average Volume (3m)

77,239

Shares Outstanding

13,189,141

Dividend Yield

PE Ratio

-0.33

Earnings Per Share (EPS)

-1.2

Revenue

2.7M

Net Profit

-15.88M

Sector

Pharmaceutical Preparations

Industry

Pharmaceutical Preparations

Website

www.acticor-biotech.com

Headquarters

Paris, Paris, Fra

Founded

1970

Acticor Biotech is listed in the Pharmaceutical Preparations sector of the Euronext with ticker ALACT. The last closing price for Acticor Biotech was 0.38 €. Over the last year, Acticor Biotech shares have traded in a share price range of 0.27 € to 6.22 €.

Acticor Biotech currently has 13,189,141 shares outstanding. The market capitalization of Acticor Biotech is 5.28 € million. Acticor Biotech has a price to earnings ratio (PE ratio) of -0.33.

ACTICOR BIOTECH: Postponement of the Publication of Annual Results and Universal Registration Document 2023

Regulatory News: ACTICOR BIOTECH (FR0014005OJ5 - ALACT), a clinical-stage biotechnology company focused on the development of glenzocimab, an innovative drug for the treatment of cardiovascular...

ACTICOR BIOTECH : Résultats principaux de l’étude de phase 2/3 ACTISAVE dans le traitement de l’AVC

L’analyse du critère principal et du critère secondaire de l’étude de phase 2/3 ACTISAVE ne montre pas d’efficacité du glenzocimab Les principales données de cette étude seront présentées à...

Acticor Biotech will Present the Clinical Results of Its Phase 2/3 ACTISAVE Study in the Treatment of Stroke at ESOC 2024

Results of ACTISAVE phase 2/3 clinical study in stroke expected in Q2 2024 Presentation of results during ESOC from 15 to 17 May 2024 Regulatory News: ACTICOR BIOTECH (ISIN: FR0014005OJ5 –...

ACTICOR BIOTECH: Information mensuelle relative au nombre total de droits de vote et d'actions composant le capital social au 31 mars 2024

Article 223-16 du Règlement Général de l'Autorité des Marchés Financiers Regulatory News: ACTICOR BIOTECH (ISIN : FR0014005OJ5 – ALACT) (Paris:ALACT), société biopharmaceutique au stade clinique...

ACTICOR BIOTECH: Disclosure of the Total Number of Voting Rights and Shares as of February 29, 2024

Regulatory News: ACTICOR BIOTECH (FR0014005OJ5 - ALACT) (Paris:ALACT), a clinical stage biopharmaceutical company developing glenzocimab, an innovative drug for the treatment of cardiovascular...

Acticor Biotech réalise avec succès une augmentation de capital d’un montant total de 8 millions d'euros

Regulatory News: Ne pas diffuser, publier ou distribuer, directement ou indirectement, aux Etats-Unis d'Amérique, au Canada, en Australie ou au Japon. Ce communiqué de presse ne constitue pas un...

Acticor Biotech lance une augmentation de capital de 7 M€ au minimum

Augmentation de capital composée d’une offre à des investisseurs qualifiés, à des catégories d’investisseurs, ainsi qu’aux investisseurs individuels via la plateforme PrimaryBid Engagements de...

The University of Birmingham and Acticor Biotech announce the First Patient treated in LIBERATE, first clinical trial evaluating glenzocimab for heart attack

University of Birmingham and Acticor Biotech News ReleaseLimited clinical access available The University of Birmingham and Acticor Biotech announce the First Patient treated in LIBERATE, first...

L'Université de Birmingham et Acticor Biotech annoncent le traitement du premier patient dans l'étude clinique LIBERATE

LIBERATE, première étude clinique évaluant le glenzocimab dans le traitement de l'infarctus du myocarde Regulatory News: L'Université de Birmingham et Acticor Biotech (Paris:ALACT) sont fiers...

Acticor Biotech has just and timely completed patient recruitment of its phase 2/3 study in stroke

Acticor Biotech has just and timely completed patient recruitment of its phase 2/3 study in stroke 438 patients with stroke have been randomized in ACTISAVE study evaluating glenzocimab, in...

Period	Change	Change %	Open	High	Low	Avg. Daily Vol	VWAP
1	0.056	16.091954023	0.348	0.48	0.337	188528	0.39747823	DE
4	-3.036	-88.2558139535	3.44	4.21	0.27	180754	0.54597587	DE
12	-4.046	-90.9213483146	4.45	5.3	0.27	77239	1.17262169	DE
26	-3.346	-89.2266666667	3.75	5.32	0.27	41453	1.55674628	DE
52	-5.256	-92.8621908127	5.66	6.22	0.27	21066	1.70301462	DE
156	-1.196	-74.75	1.6	11	0.27	29040	2.73025137	DE
260	0.024	6.31578947368	0.38	11	0.11	64494	1.18936308	DE

Most Active
% Gainers
% Losers

Symbol	Price	Vol.
NUVOHoldco Nuvo Group DG Ltd	$ 5.365 (162.99%)	41.35M
XBPXBP Europe Holdings Inc	$ 3.245 (53.07%)	53.59M
PRFTPerficient Inc	$ 73.405 (52.58%)	9.54M
PLTNPlutoniam Acquisition Corporation	$ 9.00 (49.75%)	73.44k
MULNMullen Automotive Inc	$ 6.025 (44.66%)	20.86M
LYRALyra Therapeutics Inc	$ 0.4976 (-87.65%)	100.82M
GLYCGlycoMimetics Inc	$ 0.3301 (-81.96%)	35.38M
EYPTEyePoint Pharmaceuticals Inc	$ 11.31 (-42.71%)	7.75M
LGHLWLion Group Holding Ltd	$ 0.0047 (-32.86%)	95.13k
MNDRMobile health Network Solutions	$ 2.48 (-26.84%)	8.96M
LYRALyra Therapeutics Inc	$ 0.4976 (-87.65%)	100.82M
MARAMarathon Digital Holdings Inc	$ 20.68 (18.04%)	75.62M
SQQQProShares UltraPro Short QQQ	$ 10.7901 (-2.62%)	75.43M
TSLATesla Inc	$ 184.30 (1.72%)	72.53M
NKLANikola Corporation	$ 0.66015 (0.40%)	69.12M